224 related articles for article (PubMed ID: 22123060)
1. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
[TBL] [Abstract][Full Text] [Related]
2. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
4. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
6. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
7. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract][Full Text] [Related]
8. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
[TBL] [Abstract][Full Text] [Related]
9. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
Huang S; Peet CR; Saker J; Li C; Armstrong EA; Kragh M; Pedersen MW; Harari PM
Mol Cancer Ther; 2013 Dec; 12(12):2772-81. PubMed ID: 24130052
[TBL] [Abstract][Full Text] [Related]
10. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
11. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
Spangler JB; Manzari MT; Rosalia EK; Chen TF; Wittrup KD
J Mol Biol; 2012 Sep; 422(4):532-44. PubMed ID: 22706026
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
13. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.
Ferraro DA; Gaborit N; Maron R; Cohen-Dvashi H; Porat Z; Pareja F; Lavi S; Lindzen M; Ben-Chetrit N; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1815-20. PubMed ID: 23319610
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
16. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
[TBL] [Abstract][Full Text] [Related]
17. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
18. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
19. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
[TBL] [Abstract][Full Text] [Related]
20. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]